Intragastric balloon (IGB) is used in the treatment of obesity for more than 20 years, both as a self-standing procedure and as a bridge treatment to bariatric surgery. The indications and results are well known, due to its characteristics as a non-surgical, endoscopic, minimally invasive and temporary treatment. Recently new models of IGB appeared on the market, and FDA approved for the first time in 2015 two models as treatment of obesity in the United States. Spatz™ Adjustable Balloon System is the first adjustable IGB, tolerated for 12 months, available from 2005. Between 2013-2015 thirty overweighted/obese patients were treated with Spatz3™, maintained in place for approximately 12 months, with a minimum follow-up of 6 months. The results, complications and efficacy of the Spatz3™ balloon are presented, together with an extended review of the literature. IGB represents a useful tool in the treatment of obesity, when patient’s selection is careful done.
Intragastric balloon: is there any place left for It in the treatment of obesity? / Boru, C.; Constantinicã, V.; Mavru, M.; Ulmeanu, D. I.; Puscasu, A.. - In: CHIRURGIA. - ISSN 1221-9118. - STAMPA. - 111:2(2016), pp. 193-193. (Intervento presentato al convegno THE SEVENTH NATIONAL SYMPOSIUM OF BARIATRIC AND METABOLIC SURGERY “Continous Progress in Metabolic Surgery” International Federation for Surgery of Obesity (IFSO) Endorsed Scientific Event tenutosi a Bucharest, Romania nel 5th December, 2016).
Intragastric balloon: is there any place left for It in the treatment of obesity?
C. Boru
Supervision
;
2016
Abstract
Intragastric balloon (IGB) is used in the treatment of obesity for more than 20 years, both as a self-standing procedure and as a bridge treatment to bariatric surgery. The indications and results are well known, due to its characteristics as a non-surgical, endoscopic, minimally invasive and temporary treatment. Recently new models of IGB appeared on the market, and FDA approved for the first time in 2015 two models as treatment of obesity in the United States. Spatz™ Adjustable Balloon System is the first adjustable IGB, tolerated for 12 months, available from 2005. Between 2013-2015 thirty overweighted/obese patients were treated with Spatz3™, maintained in place for approximately 12 months, with a minimum follow-up of 6 months. The results, complications and efficacy of the Spatz3™ balloon are presented, together with an extended review of the literature. IGB represents a useful tool in the treatment of obesity, when patient’s selection is careful done.| File | Dimensione | Formato | |
|---|---|---|---|
|
Boru_Intragastric_2016.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
43.49 kB
Formato
Adobe PDF
|
43.49 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
